Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitae Obtains Proof-Of-Mechanism Data For BACE Inhibition In Alzheimer’s

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Two programs partnered with Germany’s Boehringer Ingelheim are advancing, with a type 2 diabetes program moving into Phase II while a beta secretase inhibitor for Alzheimer’s demonstrates strong ability to decrease amyloid beta levels in the brain. Vitae went public in September, netting $48.4 million from its IPO.

Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS005616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel